anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the plant powder useful for health food, medicaments, cosmetics, etc., by making the soluble solid contents of propolis adsorbed and/or absorbed. SOLUTION: For example, Panax notoginseng (Burk.) F.H. Chen from which the terrestrial stems of the roots and the fine roots are removed and which is dried at it is prepd. Next, this Panax notoginseng (Burk.) F.H. Chen is cut and is made into powder of 100 meshes. The propolis of an eucalyptus system produced in Brazil extracted with 95v.% ethanol is prepd. to 10w/v% solid content derived from the propolis. Next, 300cc this propolis liquid is added to 200g Panax notoginseng (Burk.) F.H. Chen powder and the mixture is stirred. After the propolis liquid is adsorbed and absorbed to the Panax notoginseng (Burk.) F.H. Chen powder, the mixture is subjected to a pressure reduction at 20 to 80 deg.C, by which the ethanol is removed. The Panax notoginseng (Burk.) F.H. Chen raw powder from which the ethanol is removed is pulverized by a mill, by which the desired plant powder is obtd.
Chagas cardiomyopathy caused by infection with the intracellular parasite Trypanosoma cruzi is the most common and severe expression of human Chagas disease. Heart failure, systemic and pulmonary thromboembolism, arrhythmia, and sudden cardiac death are the principal clinical manifestations of Chagas cardiomyopathy. Ventricular arrhythmias contribute significantly to morbidity and mortality and are the major cause of sudden cardiac death. Significant gaps still exist in the understanding of the pathogenesis mechanisms underlying the arrhythmogenic manifestations of Chagas cardiomyopathy. This article will review the data from experimental studies and translate those findings to draw hypotheses about clinical observations. Human- and animal-based studies at molecular, cellular, tissue, and organ levels suggest 5 main pillars of remodeling caused by the interaction of host and parasite: immunologic, electrical, autonomic, microvascular, and contractile. Integrating these 5 remodeling processes will bring insights into the current knowledge in the field, highlighting some key features for future management of this arrhythmogenic disease.
Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
Survival rates are increasing for common pediatric cancers, including acute lymphoblastic leukemia (ALL) and brain tumors; yet, the life-saving treatments for these cancers place survivors at heightened risk for sustained cognitive effects. Longitudinal research has shown that the cognitive burden of ALL and pediatric brain tumors often consists of impairments in attention, working memory, and executive functioning, which can result in long-term disruption to daily living, socialization, academic achievement, and quality of life. Few non-pharmacological interventions exist to ameliorate these cognitive late effects. EndeavorRx, an FDA-approved electronic attentional-control training program, may be one intervention to help remediate executive functioning difficulties experienced by survivors. Although the program has been efficacious for youth with Attention-Deficit/Hyperactivity Disorder (ADHD), it has not yet been tested among survivors of childhood ALL or brain tumor. We propose to assess the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a pilot randomized, controlled trial. Survivors of ALL or brain tumor who are between the ages of 8 and 16 and have been off-therapy for at least one year will be included. The goal is to enroll and screen approximately 50 survivors across three pediatric oncology centers, in order to identify 40 participants with attention difficulties who will be randomized to one of two treatment arms. Participants will be assigned to either the EndeavorRx intervention, which includes 25-30 minute sessions per day, 5 days per week, for one month, or an active control condition of the same duration and intensity. Patients will undergo neurocognitive testing pre- and post-intervention, and parents will complete questionnaires regarding their child's functioning. It is hypothesized that this attentional-control training program will be both acceptable and feasible, with sufficient enrollment, positive satisfaction ratings, and acceptable treatment adherence. It is also anticipated that participants will show increases in performance-based and parent-rated attention, as compared to those in the active control condition.
PROBLEM TO BE SOLVED: To obtain an antidandruff composition capable of exhibiting an effective antidandruff effect and having excellent safety for scalp by adding L- ornithine or its salt as an active ingredient. SOLUTION: This antidandruff agent composition contains (A) one or more kinds of compounds selected from among L-ornithine and its salts. The component A is preferably compounded in an amount of 0.001-10.0 wt.% in the composition. If necessary, the composition may suitable be compounded with various kinds of components usually used in skin preparations for external uses, such as cosmetics, unregulated medicines and medicines. The composition may be prepared in an arbitrary preparation form, for example, a hair cosmetic such as shampoo or rinse, a hair growth stimulant such as hair tonic or a hair- dressing cosmetic such as hair liquid.  The antidandruff composition can thereby safely prevent dandruff and prevent and treat the dandruff generated on scalp stimulation caused by surfactants contained in shampoos, etc., and further makes it possible to expect a high effect on the prevention of skin itching.
BACKGROUND: Differences in border zone contribute to different outcomes post-infarction, such as left ventricular aneurysm (LVA) and myocardial infarction (MI). LVA usually forms within 24 h of the onset of MI and may cause heart rupture; however, LVA surgery is best performed 3 months after MI. Few studies have investigated the LVA model, the differences in border zones between LVA and MI, and the mechanism in the border zone.
METHODS: The LVA, MI, and SHAM mouse models were used. Echocardiography, Masson's trichrome staining, and immunofluorescence staining were performed, and RNA sequencing of the border zone was conducted. The adipocyte-conditioned medium-treated hypoxic macrophage cell line and LVA and MI mouse models were employed to determine the effects of the hub gene, adiponectin (ADPN), on macrophages. Quantitative polymerase chain reaction (qPCR), Western blot analysis, transmission electron microscopy, and chromatin immunoprecipitation (ChIP) assays were conducted to elucidate the mechanism in the border zone. Human subepicardial adipose tissue and blood samples were collected to validate the effects of ADPN.
RESULTS: A novel, simple, consistent, and low-cost LVA mouse model was constructed. LVA caused a greater reduction in contractile functions than MI owing to reduced wall thickness and edema in the border zone. ADPN impeded cardiac edema and promoted lymphangiogenesis by increasing macrophage infiltration post-infarction. Adipocyte-derived ADPN promoted M2 polarization and sustained mitochondrial quality via the ADPN/AdipoR2/HMGB1 axis. Mechanistically, ADPN impeded macrophage HMGB1 inflammation and decreased interleukin-6 (IL6) and HMGB1 secretion. The secretion of IL6 and HMGB1 increased ADPN expression via STAT3 and the co-transcription factor, YAP, in adipocytes. Based on ChIP and Dual-Glo luciferase experiments, STAT3 promoted ADPN transcription by binding to its promoter in adipocytes. In vivo, ADPN promoted lymphangiogenesis and decreased myocardial injury after MI. These phenotypes were rescued by macrophage depletion or HMGB1 knockdown in macrophages. Supplying adipocytes overexpressing STAT3 decreased collagen disposition, increased lymphangiogenesis, and impaired myocardial injury. However, these effects were rescued after HMGB1 knockdown in macrophages. Overall, the IL6/ADPN/HMGB1 axis was validated using human subepicardial tissue and blood samples. This axis could serve as an independent factor in overweight MI patients who need coronary artery bypass grafting (CABG) treatment.
CONCLUSION: The IL6/ADPN/HMGB1 loop between adipocytes and macrophages in the border zone contributes to different clinical outcomes post-infarction. Thus, targeting the IL6/ADPN/HMGB1 loop may be a novel therapeutic approach for cardiac lymphatic regulation and reduction of cell senescence post-infarction.
Standard practice. Oxygen adjustments will be made by clinical/nursing staff to maintain a target oxygen range of 90%-95%.
The present invention relates to preventing the color transfer and adhesion of a powder-containing cosmetic onto clothing. This method for producing a coating film involves an electrostatic spray step for forming a coating film on the skin by electrostatically spraying a composition directly onto the surface of the skin to which a powder-containing cosmetic has been applied. The composition contains a component (a) and a component (b), below. The method further involves a solution application step for applying a solution containing one or more of water and oils that are liquid at 20°C to the skin to which a powder-containing cosmetic has been applied, and ideally involves having the solution application step after the electrostatic spray step. (a) One or more volatile substances selected from the group consisting of water, alcohol and ketones. (b) A polymer that can form a coating film.
PROBLEM TO BE SOLVED: To obtain a monoclonal antibody having action suppressing complement-dependent cytotoxicity and useful as a preventive or treating agent for complement-dependent cytotoxicity by specifically binding to dipeptidylpeptidase IV. SOLUTION: This monoclonal antibody having action suppressing complement- dependent cytotoxicity is obtained by specifically binding to a dipeptidylpeptidase IV (hereinafter referred to as DPP IV). This monoclonal antibody is preferably a monoclonal antibody F16 using rat glomerulus as an antigen and is preferably produced from e.g. F-16 hybridoma (FERM P-17016). The monoclonal antibody is capable of expecting use as a preventive or a therapeutic agent for complement-dependent cytotoxicity. The use of DPP IV binding to the monoclonal antibody enables screening of a compound having complement activity-suppressing action.
The aim of this study is to contribute to the improvement of the hematological management of elderly patients. Indeed, the majority of hematological malignancies are diagnosed in subjects aged 65 years and over. Hematologists are therefore increasingly confronted with the complexity of managing elderly patients. The high prevalence of comorbidities and/or geriatric syndromes (cognitive disorders, malnutrition, loss of functional autonomy, etc.) contributes to the great heterogeneity of this population and to the complexity of therapeutic decisions.

The comprehensive geriatric assessment (CGA), recommended by the International Society of of Onco-Geriatrics (SIOG), allows to better understand this heterogeneity and to define an individualized management. Numerous studies have demonstrated the value of the CGA in predicting the risk of treatment toxicity and morbidity in geriatric hematology. However, beyond life expectancy, the maintenance of quality of life and/or functional autonomy represent major parameters to be integrated into the therapeutic decision. These two parameters are not sufficiently taken into account in hematology clinical trials. In the vast majority of these studies, the criteria of interest remain purely hematological (overall survival, toxicity, relapse-free survival, etc.). This approach may even be responsible for an increased risk of toxicity when the chemotherapy protocols proposed to elderly patients are based on the same objectives as those for younger subjects. It therefore seems essential to change the paradigm by integrating major geriatric criteria into the methodology of clinical trials of hematological malignancies in elderly patients.

The main objective of our study is therefore to evaluate the prevalence of functional decline in a population of elderly patients treated with chemotherapy or immuno-chemotherapy for lymphoid hemopathies. For this purpose, each patient benefits at inclusion (D0) of a standardized gerontological evaluation, and 3 and 6 months post-inclusion.
The present invention provides a nanoemulsion having reversible continuous and dispersed phases. The nano emulsion comprises a water phase and an oil phase, wherein the weight ratio of the water phase to the oil phase is 1: 40-100: 1. In this nanoemulsion, the aqueous phase is dispersed in the oil phase in the form of nano-sized droplets or the oil phase is dispersed in the aqueous phase in the form of nano-sized droplets. The aqueous phase contains water or an aqueous solution and a water-soluble organic nanostructure stabilizer. The oil phase comprises an oil or oil solution, an organogel thickener and a hydrophilic surfactant having an HLB value greater than 8.0. Also disclosed is a method for preparing the above nanoemulsion.
Provided is a method and vector for modulating apoptosis in a target cell population. Flavopiridol treatment leads to apoptosis via a mechanism associated with downregulation of Mcl-1. E2F1 leads to transcriptional repression of Mcl-1 and subsequently apoptosis. Given the ability of cyclin/cyclin-dependent kinase 2 antagonists to kill transformed cells, flavopiridol may stabilize E2F1 and enhance apoptosis via repression of Mcl-1. Flavopiridol is associated with a dose-dependent increase in E2F1 protein levels, a corresponding reduction in Mcl-1, and apoptosis in lung carcinoma cells. Treatment of cells with 200 nM flavopiridol results in the rapid elevation of E2F1 and reduction in Mcl-1 levels within 12 hours of treatment. The elevation of E2F1 and reduction in Mcl-1 clearly precedes the induction of apoptosis. Cell lines that constitutively express Mcl-1 under the control of the cytomegalovirus promoter have no reductions in Mcl-1 levels with flavopiridol treatment and are resistant to apoptosis induced by flavopiridol.
Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
The invention discloses a preparation for assisting in treating pulmonary nodules, and a preparation method, a use method and application thereof, and belongs to the technical field of traditional Chinese medicines. The reagent is based on the basic pathogenesis of lung nodule 'lung qi deficiency and phlegm stasis accumulation', and takes warming yang, dredging collaterals, activating blood, promoting qi circulation, attacking and removing stasis accumulation as a treatment principle. Bai Jie is good at dispersing to remove phlegm; rhizoma Sparganii and Curcumae rhizoma are used for removing blood stasis, resolving food stagnation, and dispersing qi and resolving hard mass; turmeric has the effects of promoting qi circulation and dredging channels; the three medicines are combined, so as to activate blood, promote qi circulation, attack and remove stasis; astragalus mongholicus is used for tonifying qi and raising yang. Herba asari, fructus Perillae and Prunellae Spica are added to exert the effects of lowering qi, resolving phlegm and resolving masses; pseudo-ginseng and cowherb seed are used as auxiliary materials, so that the effects of promoting blood circulation, removing blood stasis, promoting qi circulation and dredging channels are achieved; with the addition of the barbed skullcap herb and the oldenlandia, the medicine can remove blood stasis and dredge collaterals; dendrobium nobile has effects of nourishing yin and promoting fluid production, and pungent and cool borneol, baikal skullcap root and hibiscus leaf can clear lung and detumescence, and unblock lung collaterals, so that it can match cold and heat, and harmonize yin and yang. The external plaster is prepared and applied. The Chinese herbal medicine composition is used for auxiliary health care of lung nodules, and has great clinical significance and value.
Method and device to create energized polymers that can be used for pain relief, comprised of an ultrasound system that ultrasonically energize polymers that can then be used to provide an analgesic effect. Ultrasound waves are delivered to a polymer through direct contact, through a coupling medium, or without contact in order to energize the polymer. Other energies such as such as UV. microw ave, laser, electricity, RF, sun. light, magnetic/electromatinenc, etc can also be used to energize the polymer. The energized polymer can be immediately placed on a user to provide an analgesic effect, or the energized polymer can be placed storage material and removed at a later time to he placed on a user to provide an analgesic effect.
All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
To provide a method for treating cancer.SOLUTION: Provided are a platinum-based medicine (e.g. carboplatin) combined with an antibody-drug conjugate (e.g. Tisotumab vedotin) binding to a tissue factor (TF), and use thereof in a method for treating cancer such as bladder cancer and cervical cancer. Further, provided are a composition and a kit containing a platinum-based medicine (e.g. carboplatin) and an antibody-drug conjugate (e.g. Tisotumab vedotin) binding to TF, to be used for treating cancer such as bladder cancer and cervical cancer.SELECTED DRAWING: None
Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
The invention provides methods for treating autoimmunity and for reestablishing tolerance. The methods involve the coadministration of anti-CD3 antibodies and self-antigens. The coadministration has the potential to provide a synergistic effect of protecting or reducing autoaggressive immune processes and/or of reestablishing tolerance towards self-antigens. An underlying rationale behind the methods is that the administration of self-antigens together with anti-CD3 antibodies can alter the response to those self-antigens and prevent progression of autoimmunity. By rechallenging with the autoantigens and stimulating the non-pathogenic response, the blockade of the autoimmune process can be maintained. Preclinical evidence provided herein shows that the combination of anti-CD3 and autoantigen is synergistic in reversing autoimmune diabetes, and therefore, suggests that combination therapy of anti-CD3 and self-antigen may provide synergistic protection in reversing other autoimmune disorders.
OBJECTIVES: In systemic sclerosis (SSc), gastrointestinal involvement is one of the earliest events. We compared the gut microbiota (GM), its short-chain fatty acids (SCFAs) and host-derived free fatty acids (FFAs) in patients with very early diagnosis of SSc (VEDOSS) and definite SSc.
METHODS: Stool samples of 26 patients with SSc, 18 patients with VEDOSS and 20 healthy controls (HC) were collected. The GM was assessed through 16S rRNA sequencing, while SCFAs and FFAs were assessed by gas chromatography-mass spectrometry.
RESULTS: In patients with VEDOSS, an increase in Bacteroidales and Oscillospirales orders and a decrease in Bacilli class, Blautia, Romboutsia, Streptococcus and Turicibacter genera was detected in comparison with HC. In patients with SSc, an elevated number of Acidaminococcaceae and Sutterellaceae families, along with a decrease of the Peptostreptococcaceae family and Anaerostipes, Blautia, Romboutsia and Turicibacter genera was found in comparison with HC. Patients with SSc and VEDOSS had a significantly lower butyrate and higher acetate with respect to HC. In VEDOSS, an increase in Oscillospiraceae family and Anaerostipes genus, and a decrease in Alphaproteobacteria class, and Lactobacillales order was identified with respect to SSc. Moreover, patients with VEDOSS exhibited higher acetate and lower valerate compared with definite SSc.
CONCLUSION: A GM dysbiosis with depletion of beneficial anti-inflammatory bacteria (especially butyrate-producing) and a significant decrease in faecal butyrate was identified in patients with VEDOSS. This early GM imbalance may foster the growth of inflammatory microbes, worsening intestinal dysbiosis and inflammation in early SSc stages. The potential butyrate administration in early disease phases might be considered as a novel therapeutic approach to mitigate gastrointestinal discomfort and progression preserving patient's quality of life.
Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
<P>PROBLEM TO BE SOLVED: To prepare a multi-functional cleansing cosmetic which can simplify make-up steps.  <P>SOLUTION: This cleansing cosmetic is characterized by containing a polyoxyethylene fatty acid glyceryl ester. The average addition mole number of the polyoxyethylene of the polyoxyethylene fatty acid glyceryl ester is preferably 6 to 8. The fatty acid portion is preferably a fatty acid originated from coconut oil. Since the cleansing cosmetic prepares the state of skin into a state capable of being easily made up after the cleansing, the skin can be made up without using an underground cosmetic. Thereby, makeup steps can be simplified. Since the cleansing cosmetic dissolves soap, or the like, and has a cleansing action, the cleansing cosmetic can also be used for wiping off an aqueous cleansing preparation on aesthetics.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
<P>PROBLEM TO BE SOLVED: To provide a gel-forming composition for preparing a gel with high deformability suitable for swallowing, and the gel using the composition.  <P>SOLUTION: The gel-forming composition is constituted of tara gum and xanthan gum with high molecular weights and small degrees of dispersions of the molecular weights. Further the gel-forming composition whose deformation rate at an inflection point of a mechanical tangent loss (tanδ) for the deformation rate is 20-50% and whose mechanical tangent loss tanδ at the inflection point is 0.1-1 is obtained by an aqueous solvent and various active ingredients as required. A ratio (weight ratio) of the xanthan gum and the tara gum is 10/90 to 90/10, and a ratio of a polysaccharide thickener is 0.1-1 wt.%. The gel is highly deformable and suitable for food to be swallowed. In particular, it is appropriate for the food to be swallowed containing ingredients such as protein, peptide and vitamin.  <P>COPYRIGHT: (C)2008,JPO&INPIT